Haisco(SZ:002653) Sou Hu Cai Jing·2025-07-29 02:15Summary of Key Points Core Viewpoint - The company, Haishike, announced a plan for a major shareholder to reduce their stake in the company, which may impact the stock price and investor sentiment. The company is also in the process of raising funds for new drug development and working capital through a specific stock issuance. Group 1: Shareholder Actions - The controlling shareholder's associate, Shen Ping, plans to reduce their holdings by up to 10.37 million shares, representing a maximum of 0.926% of the total share capital within three months after the announcement [1] - The estimated cash amount from this reduction, based on the closing price of 48.2 yuan per share, is approximately 500 million yuan [1] - As of the announcement date, the controlling shareholder, Wang Junmin, holds 35.68% of the shares, while Shen Ping holds 4.43%, totaling 40.11% for the couple [1] Group 2: Financial Performance and Projections - In 2024, Haishike's revenue is projected to be 3.721 billion yuan, reflecting a year-on-year growth of 10.92%, with a net profit attributable to shareholders of 395 million yuan, up 34% [4] - For the first quarter of 2025, the company reported revenue of 892 million yuan, an increase of 18.6% year-on-year, but the net profit attributable to shareholders decreased by 49.31% to 46.61 million yuan [5] Group 3: Fundraising and Investment Plans - The company plans to raise up to 1.365 billion yuan through a specific stock issuance, with funds allocated for new drug research and development and to supplement working capital [3] - The total investment for the new drug development project is approximately 965.26 million yuan, while 400 million yuan is earmarked for working capital [4]